rs777790000
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_003640.5(ELP1):c.856G>C(p.Glu286Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000384 in 1,613,578 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. E286E) has been classified as Likely benign.
Frequency
Consequence
NM_003640.5 missense
Scores
Clinical Significance
Conservation
Publications
- primary dysautonomiaInheritance: AR Classification: DEFINITIVE Submitted by: Myriad Women’s Health
- Riley-Day syndromeInheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, Orphanet
- medulloblastomaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ELP1 | NM_003640.5 | c.856G>C | p.Glu286Gln | missense_variant | Exon 9 of 37 | ENST00000374647.10 | NP_003631.2 | |
| ELP1 | NM_001318360.2 | c.514G>C | p.Glu172Gln | missense_variant | Exon 9 of 37 | NP_001305289.1 | ||
| ELP1 | XM_047423991.1 | c.856G>C | p.Glu286Gln | missense_variant | Exon 9 of 25 | XP_047279947.1 | ||
| ELP1 | NM_001330749.2 | c.-192G>C | 5_prime_UTR_variant | Exon 7 of 35 | NP_001317678.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151926Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000795 AC: 2AN: 251472 AF XY: 0.00000736 show subpopulations
GnomAD4 exome AF: 0.0000410 AC: 60AN: 1461652Hom.: 0 Cov.: 33 AF XY: 0.0000399 AC XY: 29AN XY: 727154 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151926Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74176 show subpopulations
ClinVar
Submissions by phenotype
not provided Uncertain:2
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 286 of the ELP1 protein (p.Glu286Gln). This variant is present in population databases (rs777790000, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with ELP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 566741). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt ELP1 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not specified Uncertain:1
The c.856G>C (p.E286Q) alteration is located in exon 9 (coding exon 8) of the IKBKAP gene. This alteration results from a G to C substitution at nucleotide position 856, causing the glutamic acid (E) at amino acid position 286 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Familial dysautonomia Uncertain:1
- -
Familial dysautonomia;C0025149:Medulloblastoma Uncertain:1
- -
Medulloblastoma Uncertain:1
The ELP1 c.856G>C (p.Glu286Gln) missense change has a maximum subpopulation frequency of 0.002% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. To our knowledge, this variant has not been reported in individuals with a personal or family history of medulloblastoma. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at